Mode
Text Size
Log in / Sign up
N/A N=20 Treatment

Immediate Placement and Stabilization of Dental Implants With Tetranite Stabilization Material in Mandibular and Maxillary Tooth Extraction Sites That Fail to Provide Adequate Primary Stability

Adhesive Dental

Enrolled (actual)
20
Serious AEs
65.0%
Results posted
Feb 2024
Primary outcome: Primary: Implant Success (Modified Buser Criteria) — 6 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Tetranite (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
RevBio
Primary completion
Mar 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Implant Success (Modified Buser Criteria)
6
SECONDARY
Adverse Events (Serious, Device Related)

Summary

This study is to determine if a new bone adhesive is useful in stabilizing dental tooth implants. Data collected from the study will examine the strength, performance, and the safety of the material.

Eligibility Criteria

Inclusion Criteria

  • Signed Informed Consent;
  • 21+ Age;
  • Require tooth extraction and replacement with dental implant;
  • Have opposing dentition;
  • Committed to Study and Follow-up period;
  • ASA I or II;
  • Planned "implant site" must have 1 adjacent tooth;
  • Sufficient bone Height for safe dental implant placement;
  • At least 2 mm of apical bone for seating of implant.

Exclusion Criteria

  • Any significant disease that would preclude a dental implant
  • Any oral surgery contraindications
  • Subjects with mucosal Disease
  • Subjects with bone diseases or conditions (e.g. Paget's disease, fibrous dysplasia, history of osteomyelitis, etc.) in the region of the potential study implant site;
  • Subjects with a history of local radiation therapy in the head/neck area or osteonecrosis of the jaws;
  • Subjects with any acute and untreated endodontic lesions or periodontal disease;
  • Subjects receiving, or having a recent or long-term history of receiving, oral or parenteral anti-osteoclastic agents [e.g., bisphosphonates, Xgeva® and Prolia® (denosumab); Forteo® (teriparatide), strontium ranelate, etc.], or anti-angiogenesis factors;
  • Subjects who have major active substance abuse problems (e.g., alcoholism, opiate addiction, methamphetamine abuse, etc.);
  • Subjects who are pregnant or intending to become pregnant during the duration of the study;
  • Subjects who are heavy smokers (defined as >10 cigarettes per day or >1 cigar per day or equivalent of electronic cigarette vaping) or chew tobacco;
  • Subjects with inadequate oral hygiene or who are unmotivated for adequate home care;
  • Subjects who have physical or mental handicaps that would interfere with the ability to perform adequate oral hygiene;
  • Subjects who have undergone administration of any investigational device within 30 days of enrollment in the study;
  • Subjects who are allergic or otherwise sensitive to any materials likely encountered during the course of the study (e.g. titanium, suture materials, local anesthetics);
  • Subjects with conditions or circumstances, which, in the opinion of the Investigator, would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability
  • Any site into which the implant is not or cannot be placed during the same visit as the extraction;
  • Any implant site where there is a dehiscence or fenestration of buccal or lingual plates of bone greater than 5mm in any direction.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04121364). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search